GM's New LMR Battery Could Change the Game: Is it Ready to Lead?
These new batteries are designed for GM's full-size electric trucks and SUVs like the Chevrolet Silverado EV and the Cadillac Escalade IQ. The LMR chemistry swaps out pricey materials like nickel and cobalt for more common and affordable manganese. This shift not only cuts raw material costs but could also help GM improve the range and weight efficiency of its EVs.
GM claims that LMR batteries offer 33% higher energy density than today's top lithium iron phosphate (LFP) cells, all while maintaining comparable costs. This means more miles per charge without driving up sticker prices.
Production is already on the horizon. Ultium Cells, GM's joint venture with LG Energy Solution, aims to begin preproduction in late 2027 and full commercial production in 2028. It's all part of GM's broader push to scale its Ultium platform and improve EV profitability.
But GM isn't the only auto giant chasing this battery breakthrough. Ford F is also in the race, and it's moving fast. Last month, the company announced that it is developing its own LMR battery chemistry at its Ion Park R&D center in Michigan. Ford has already begun pilot production of second-generation cells and aims to roll out LMR-powered EVs before the decade ends.
Ford sees LMR as the 'what's next' solution following its current use of nickel-manganese-cobalt (NMC) and LFP batteries. The company believes the chemistry could unlock longer-range, lower-cost EVs, especially crucial for scaling up mass-market adoption.
Tesla TSLA, meanwhile, planted early seeds in this space. CEO Elon Musk floated the idea of high-manganese batteries as far back as 2020 during Tesla's 'Battery Day.' At the time, he said Tesla aimed to create cathodes with one-third manganese content to stretch its nickel supply further. Tesla holds patents related to LMR chemistry, but it is yet to share firm production plans.
GM looks set to be the first to market with LMR batteries, Ford is close behind, while Tesla's earlier concepts still await a clear update.
The Zacks Rundown for General Motors
Shares of General Motors have lost around 6% year to date compared with the industry's decline of 13%.
From a valuation standpoint, GM trades at a forward price-to-earnings ratio of just 5.28, significantly below the industry. It carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for GM's 2025 sales and EPS implies a 6% and 12% decline, respectively, year on year. Estimates have been southbound over the past 30 days for the current and next quarter, as well as for 2025 and 2026.
GM stock currently carries a Zacks Rank #5 (Strong Sell).
You can see
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ford Motor Company (F): Free Stock Analysis Report
General Motors Company (GM): Free Stock Analysis Report
Tesla, Inc. (TSLA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
10 minutes ago
- National Post
Cybin Announces Results of Annual Meeting of Shareholders
Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the ' Meeting '). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: Article content 1. Appointment of Auditor Article content Article content Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below: Article content 2. Number of Directors Article content The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below: Article content 3. Election of Directors Article content Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below: Article content George Tziras did not stand for re-election as a director. The Company thanks Mr. Tziras for his past service. Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Article content Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Investor & Media Contact: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content
Globe and Mail
10 minutes ago
- Globe and Mail
Wall Street holds at a standstill near its record heights
NEW YORK (AP) — Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from the head of the Federal Reserve and from some of the biggest U.S. retailers. The S&P 500 barely budged and fell by less than 0.1%, coming off its first loss after setting an all-time high in three consecutive days. The Dow Jones Industrial Average slipped 33 points, or 0.1%, and the Nasdaq composite edged up by less than 0.1%. Novo Nordisk's stock that trades in the United States rose 3.7% after the Danish company said U.S. regulators approved its Wegovy drug as part of a treatment for a liver disease found in many overweight and obese people. Soho House, a membership club with locations around the world, jumped 14.9% after announcing a deal where an investor group led by hotel-operator MCR would pay $9 in cash for its shares. Several of the country's largest retailers, meanwhile, were mixed ahead of their profit reports that are scheduled for later in the week. Home Depot, which will report on Tuesday, slipped 1.2%. Target rose 1.9% ahead of its report on Wednesday, and Walmart added 0.7% before its report on Thursday. They, along with companies like Estee Lauder and Ross Stores, could offer a look at how different types of U.S. households are holding up when the job market seems to have morphed into one where relatively few workers are getting fired but also hired. Just like a small group of wealthy households are separating from the rest of the country, a handful of Big Tech companies are dominating the U.S. stock market, in part because of a boom in spending around artificial-intelligence technology. This separation of 'haves' and 'have nots' in the stock market could be increasing the risk, with many companies potentially facing trouble if the economy stagnates and inflation is high, according to Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management. The danger is that investors could look at how much the broad S&P 500 index has surged since its low point in April and 'extrapolate the success of the few to the gains of the many.' On Friday, the focus will swing to Jackson Hole, Wyoming, which has been the home in past years of many big policy announcements from the Federal Reserve. There, Fed Chair Jerome Powell will give a speech, and investors are hoping to hear how his mind has changed about interest rates since he said last month that he wanted to wait longer before cutting interest rates. The fear at that time was that President Donald Trump's tariffs could push inflation higher. Now, though, the bigger fear could be the slowing U.S. job market following a disappointingly weak report on employment that arrived just after the Fed's last meeting. The Fed's twin jobs are to keep the job market healthy while also maintaining a lid on inflation, and helping one can often hurt the other in the short term. Lower rates can boost the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment, for example, but they also risk worsening inflation. Inflation updates since the Fed's last meeting have come in mixed, further muddying the picture, but traders are nevertheless strongly expecting the Fed to cut its main interest rate for the first time this year at its next meeting in September. The hope is that Powell could give a nod to that. Expectations for cuts to interest rates have pulled Treasury yields lower lately, and they largely remained there on Monday. The yield on the 10-year Treasury held at 4.33%, where it was late Friday. On Wall Street, the S&P 500 edged down 0.65 to 6,449.15. The Dow Jones Industrial Average slipped 34.30 to 44,911.82, and the Nasdaq composite added 6.80 to 21,629.77. In stock markets abroad, indexes mostly fell in Europe in their first trading after Trump's inconclusive summit meeting with Russian President Vladimir Putin on Friday about the war in Ukraine. Trump met with Ukrainian President Volodymyr Zelenskyy on Monday. In Asia, indexes were mixed, with Japan's Nikkei 225 rising 0.8% and South Korea's Kospi falling 1.5%.
National Post
10 minutes ago
- National Post
Capvidia brings MBD for Suppliers with browser-based 3D human-viewable models linked to QIF/STEP
Article content CHICAGO — Capvidia, a global leader in Model-Based Definition (MBD) and Model-Based Enterprise (MBE) software, announced a major milestone for MBDVidia: 3D human-viewable HTML models synchronized with QIF and STEP AP242. The result is OEM MBD that suppliers can use anywhere with no CAD required. Article content How it works: Article content Article content MBDVidia publishes standards-based QIF/STEP from native CAD (Creo, CATIA, SOLIDWORKS, Autodesk, etc.) and now generates a linked HTML viewable (and PDF). Any browser can open the interactive 3D model and PMI, giving procurement, manufacturing, quality, and the shop floor a shared, authoritative view in a user-friendly way. Article content Why it matters for Suppliers: Article content No CAD seats: Open interactive 3D + PMI in any modern browser. Faster RFQs: See features, GD&T, and tolerances in 3D to quote accurately. Fewer errors: Viewable is linked to QIF/STEP and native CAD—preserves intent. Bill of Characteristics click-through: Jump from each characteristic to the exact PMI on the model. Shop-floor friendly: Zoom, section, filter PMI; run on tablets or kiosks. Quality ready: Linked QIF speeds FAI/PPAP and audit-ready traceability. Clear changes: Model-to-characteristic traceability improves ECO handling. Start 2D → scale 3D: Use HTML as a low-friction on-ramp from PDFs. 'Capvidia is about simplifying collaboration between OEMs and suppliers,' said Tomasz Luniewski, CEO of Capvidia. 'By pairing standards-based QIF/STEP with an interactive browser view, we make MBD universally accessible so quoting, programming, and quality teams can move faster with fewer mistakes.' Article content Learn more: MBDVidia at Get MBD ready: Request a demo at About Capvidia Capvidia is the global authority on MBD/MBE. We make the 3D model the single source of truth, auto-generating PMI and characteristics to eliminate manual ballooning and automate workflows from design through quality. Built on open standards (QIF, STEP AP242) and native CAD, our software delivers true interoperability across CAD, CAM, CMM, and PLM—without loss of intent. The result is a complete, auditable, traceable digital thread linking every requirement to real-world results across OEMs and suppliers. Trusted by leading aerospace, defense, medical-device, and industrial manufacturers, Capvidia helps teams move faster, prove conformance, and collaborate with confidence. Article content Article content Article content
